The FDA authorized the use of a new Covid-19 antibody drug from Eli Lilly that retains effectiveness against the Omicron variant, filling a void after authorities stopped distributing some older antibody drugs that lost effectiveness against the strain
U.S. drug regulators authorized the use of a new Covid-19 antibody drug from Eli Lilly & Co. that retains effectiveness against the Omicron variant of the virus, filling a void after authorities stopped distributing some older antibody drugs that lost effectiveness against the strain.
The Food and Drug Administration on Friday cleared the drug, bebtelovimab, for the treatment of mild to moderate Covid-19 in nonhospitalized individuals 12 and older who are at high risk of getting severely sick. The drug is intended for people who can’t get access to alternative Covid-19 treatments, or for whom those treatments aren’t appropriate.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
U.S. to buy 600,000 doses of Eli Lilly COVID treatmentThe U.S. is set to buy 600,000 doses of Eli Lilly’s developmental drug bebtelovimab, an antibody treatment that’s been found to neutralize COVID variants including Omicron.
Weiterlesen »
FDA Committee Votes Against Eli Lilly Cancer Treatment Over Concerns Trials Conducted Only in ChinaFDA committee members said the trial population of mostly Asian men did not represent the diversity of U.S. patients.
Weiterlesen »
In reversal, FDA puts brakes on COVID shots for kids under 5The shots for kids may not be reviewed until April.
Weiterlesen »
Pfizer pulls FDA request for COVID-19 vaccine for kids under 5The company said it believes three doses “may provide a higher level of protection in this age group.”
Weiterlesen »
US preps 10 million doses of COVID-19 vaccine for kids under 5, pending FDA authorizationCOVID-19 vaccines for kids under 5 have not yet been authorized, but the rollout plan is already in the works.
Weiterlesen »
Young kids’ COVID vaccines create approval dilemma for FDATwo doses of Pfizer's vaccine showed mixed results in trials, but the agency is considering approving it anyways in anticipation that a future third shot will provide children with strong immunity.
Weiterlesen »